U.S. Department of Health & Human Services Divider Arrow National Institutes of Health Divider Arrow NCATS

Details

Stereochemistry ABSOLUTE
Molecular Formula C21H24FN3O4
Molecular Weight 401.4314
Optical Activity UNSPECIFIED
Defined Stereocenters 2 / 2
E/Z Centers 0
Charge 0

SHOW SMILES / InChI
Structure of MOXIFLOXACIN

SMILES

[H][C@]12CN(C[C@@]1([H])NCCC2)C3=C(OC)C4=C(C=C3F)C(=O)C(=CN4C5CC5)C(O)=O

InChI

InChIKey=FABPRXSRWADJSP-MEDUHNTESA-N
InChI=1S/C21H24FN3O4/c1-29-20-17-13(19(26)14(21(27)28)9-25(17)12-4-5-12)7-15(22)18(20)24-8-11-3-2-6-23-16(11)10-24/h7,9,11-12,16,23H,2-6,8,10H2,1H3,(H,27,28)/t11-,16+/m0/s1

HIDE SMILES / InChI

Molecular Formula C21H24FN3O4
Molecular Weight 401.4314
Charge 0
Count
Stereochemistry ABSOLUTE
Additional Stereochemistry No
Defined Stereocenters 2 / 2
E/Z Centers 0
Optical Activity UNSPECIFIED

Description
Curator's Comment: description was created based on several sources, including https://www.ncbi.nlm.nih.gov/pubmed/16337789 | https://www.ncbi.nlm.nih.gov/pubmed/20516287 | https://www.ncbi.nlm.nih.gov/pubmed/25801151 | https://www.ncbi.nlm.nih.gov/pubmed/11600361

Moxifloxacin is a synthetic antibacterial agent developed by Bayer AG (initially called BAY 12-8039) for oral and intravenous administration. Moxifloxacin, a fluoroquinolone, is available as the monohydrochloride salt of 1-cyclopropyl-7-[(S,S)-2,8diazabicyclo[4.3.0]non-8-yl]-6-fluoro-8-methoxy-1,4-dihydro-4-oxo-3 quinoline carboxylic acid. Moxifloxacin is marketed worldwide (as the hydrochloride) under the brand names Avelox, Avalox, and Avalon for oral treatment. In most countries, the drug is also available in the parenteral form for intravenous infusion. Moxifloxacin is also sold in an ophthalmic solution (eye drops) under the brand names Vigamox, and Moxeza for the treatment of conjunctivitis (pink eye). Its antibacterial spectrum includes enteric Gram-(−) rods (Escherichia coli, Proteus species, Klebsiella species), Haemophilus influenzae, atypical bacteria (Mycoplasma, Chlamydia, Legionella), and Streptococcus pneumoniae, and anaerobic bacteria. It differs from earlier antibacterials of the fluoroquinolone class such as levofloxacin and ciprofloxacin in having greater activity against Gram-positive bacteria and anaerobes.

CNS Activity

Curator's Comment: http://www.accessdata.fda.gov/drugsatfda_docs/label/2016/021085s061s062,021277s057s058lbl.pdf

Approval Year

Targets

Targets

Primary TargetPharmacologyConditionPotency
800.0 nM [IC50]
9200.0 nM [IC50]
Conditions

Conditions

ConditionModalityTargetsHighest PhaseProduct
Curative
AVELOX

Approved Use

INDICATIONS AND USAGE AVELOX is a fluoroquinolone antibacterial indicated for treating infections in adults 18 years of age and older caused by designated susceptible bacteria, in the conditions listed below: Community Acquired Pneumonia, Skin and Skin Structure Infections: Uncomplicated and Complicated, Complicated Intra-Abdominal Infections, Plague, Acute Bacterial Sinusitis, Acute Bacterial Exacerbation of Chronic Bronchitis, To reduce the development of drug-resistant bacteria and maintain the effectiveness of AVELOX and other antibacterial drugs. AVELOX should be used only to treat or prevent infections that are proven or strongly suspected to be caused by susceptible bacteria.

Launch Date

9.4469757E11
Curative
AVELOX

Approved Use

INDICATIONS AND USAGE AVELOX is a fluoroquinolone antibacterial indicated for treating infections in adults 18 years of age and older caused by designated susceptible bacteria, in the conditions listed below: Community Acquired Pneumonia, Skin and Skin Structure Infections: Uncomplicated and Complicated, Complicated Intra-Abdominal Infections, Plague, Acute Bacterial Sinusitis, Acute Bacterial Exacerbation of Chronic Bronchitis, To reduce the development of drug-resistant bacteria and maintain the effectiveness of AVELOX and other antibacterial drugs. AVELOX should be used only to treat or prevent infections that are proven or strongly suspected to be caused by susceptible bacteria.

Launch Date

9.4469757E11
Curative
AVELOX

Approved Use

INDICATIONS AND USAGE AVELOX is a fluoroquinolone antibacterial indicated for treating infections in adults 18 years of age and older caused by designated susceptible bacteria, in the conditions listed below: Community Acquired Pneumonia, Skin and Skin Structure Infections: Uncomplicated and Complicated, Complicated Intra-Abdominal Infections, Plague, Acute Bacterial Sinusitis, Acute Bacterial Exacerbation of Chronic Bronchitis, To reduce the development of drug-resistant bacteria and maintain the effectiveness of AVELOX and other antibacterial drugs. AVELOX should be used only to treat or prevent infections that are proven or strongly suspected to be caused by susceptible bacteria.

Launch Date

9.4469757E11
Cmax

Cmax

ValueDoseCo-administeredAnalytePopulation
3.1 mg/L
400 mg single, oral
dose: 400 mg
route of administration: Oral
experiment type: SINGLE
co-administered:
MOXIFLOXACIN plasma
Homo sapiens
population: HEALTHY
age: ADULT
sex: UNKNOWN
food status: UNKNOWN
4.2 mg/L
400 mg 1 times / day multiple, intravenous
dose: 400 mg
route of administration: Intravenous
experiment type: MULTIPLE
co-administered:
MOXIFLOXACIN plasma
Homo sapiens
population: HEALTHY
age: ADULT
sex: MALE
food status: UNKNOWN
3.9 mg/L
400 mg single, intravenous
dose: 400 mg
route of administration: Intravenous
experiment type: SINGLE
co-administered:
MOXIFLOXACIN plasma
Homo sapiens
population: HEALTHY
age: ADULT
sex: FEMALE / MALE
food status: UNKNOWN
4.5 mg/L
400 mg 1 times / day multiple, oral
dose: 400 mg
route of administration: Oral
experiment type: MULTIPLE
co-administered:
MOXIFLOXACIN plasma
Homo sapiens
population: HEALTHY
age: ADULT
sex: FEMALE / MALE
food status: UNKNOWN
443.07 ng/ml
1 drop 4 times / day multiple, ocular
dose: 1 drop
route of administration: ocular
experiment type: multiple
co-administered:
MOXIFLOXACIN aqueous humor
Homo sapiens
population: unhealthy
age:
sex:
food status:
AUC

AUC

ValueDoseCo-administeredAnalytePopulation
36.1 mg × h/L
400 mg single, oral
dose: 400 mg
route of administration: Oral
experiment type: SINGLE
co-administered:
MOXIFLOXACIN plasma
Homo sapiens
population: HEALTHY
age: ADULT
sex: UNKNOWN
food status: UNKNOWN
38 mg × h/L
400 mg 1 times / day multiple, intravenous
dose: 400 mg
route of administration: Intravenous
experiment type: MULTIPLE
co-administered:
MOXIFLOXACIN plasma
Homo sapiens
population: HEALTHY
age: ADULT
sex: MALE
food status: UNKNOWN
39.3 mg × h/L
400 mg single, intravenous
dose: 400 mg
route of administration: Intravenous
experiment type: SINGLE
co-administered:
MOXIFLOXACIN plasma
Homo sapiens
population: HEALTHY
age: ADULT
sex: FEMALE / MALE
food status: UNKNOWN
48 mg × h/L
400 mg 1 times / day multiple, oral
dose: 400 mg
route of administration: Oral
experiment type: MULTIPLE
co-administered:
MOXIFLOXACIN plasma
Homo sapiens
population: HEALTHY
age: ADULT
sex: FEMALE / MALE
food status: UNKNOWN
T1/2

T1/2

ValueDoseCo-administeredAnalytePopulation
13.55 h
400 mg single, oral
dose: 400 mg
route of administration: Oral
experiment type: SINGLE
co-administered:
MOXIFLOXACIN plasma
Homo sapiens
population: HEALTHY
age: ADULT
sex: UNKNOWN
food status: UNKNOWN
14.8 h
400 mg 1 times / day multiple, intravenous
dose: 400 mg
route of administration: Intravenous
experiment type: MULTIPLE
co-administered:
MOXIFLOXACIN plasma
Homo sapiens
population: HEALTHY
age: ADULT
sex: MALE
food status: UNKNOWN
11.8 h
400 mg single, intravenous
dose: 400 mg
route of administration: Intravenous
experiment type: SINGLE
co-administered:
MOXIFLOXACIN plasma
Homo sapiens
population: HEALTHY
age: ADULT
sex: FEMALE / MALE
food status: UNKNOWN
12.7 h
400 mg 1 times / day multiple, oral
dose: 400 mg
route of administration: Oral
experiment type: MULTIPLE
co-administered:
MOXIFLOXACIN plasma
Homo sapiens
population: HEALTHY
age: ADULT
sex: FEMALE / MALE
food status: UNKNOWN
Funbound

Funbound

ValueDoseCo-administeredAnalytePopulation
60%
400 mg single, oral
dose: 400 mg
route of administration: Oral
experiment type: SINGLE
co-administered:
MOXIFLOXACIN plasma
Homo sapiens
population: HEALTHY
age: ADULT
sex: UNKNOWN
food status: UNKNOWN
60%
400 mg single, intravenous
dose: 400 mg
route of administration: Intravenous
experiment type: SINGLE
co-administered:
MOXIFLOXACIN plasma
Homo sapiens
population: HEALTHY
age: ADULT
sex: FEMALE / MALE
food status: UNKNOWN
Doses

Doses

DosePopulationAdverse events​
600 mg 1 times / day multiple, oral
Higher than recommended
Dose: 600 mg, 1 times / day
Route: oral
Route: multiple
Dose: 600 mg, 1 times / day
Sources: Page: p.5
healthy, 30±7
n = 7
Health Status: healthy
Age Group: 30±7
Sex: M
Population Size: 7
Sources: Page: p.5
800 mg single, oral
Highest studied dose
Dose: 800 mg
Route: oral
Route: single
Dose: 800 mg
Sources: Page: p.2062
healthy, 33.6
n = 8
Health Status: healthy
Age Group: 33.6
Sex: M
Population Size: 8
Sources: Page: p.2062
400 mg 1 times / day multiple, intravenous
Recommended
Dose: 400 mg, 1 times / day
Route: intravenous
Route: multiple
Dose: 400 mg, 1 times / day
Sources: Page: p.8.9
unhealthy, 50
Health Status: unhealthy
Condition: Bacterial infections
Age Group: 50
Sex: M+F
Sources: Page: p.8.9
Disc. AE: Rash...
AEs leading to
discontinuation/dose reduction:
Rash
Sources: Page: p.8.9
400 mg 1 times / day multiple, oral
Recommended
Dose: 400 mg, 1 times / day
Route: oral
Route: multiple
Dose: 400 mg, 1 times / day
Sources: Page: p.8.9
unhealthy, 50
Health Status: unhealthy
Condition: Bacterial infections
Age Group: 50
Sex: M+F
Sources: Page: p.8.9
Disc. AE: Nausea, Diarrhea...
AEs leading to
discontinuation/dose reduction:
Nausea (>0.3)
Diarrhea (>0.3)
Dizziness (>0.3)
Vomiting (>0.3)
Sources: Page: p.8.9
800 mg 1 times / day multiple, oral
Highest studied dose
Dose: 800 mg, 1 times / day
Route: oral
Route: multiple
Dose: 800 mg, 1 times / day
Sources: Page: p.7
unhealthy, 57.8
n = 5
Health Status: unhealthy
Condition: Chronic bronchitis
Age Group: 57.8
Sex: M+F
Population Size: 5
Sources: Page: p.7
400 mg 1 times / day multiple, oral|intravenous
Recommended
Dose: 400 mg, 1 times / day
Route: oral|intravenous
Route: multiple
Dose: 400 mg, 1 times / day
Co-administed with::
Linezolid, IV(600 mg q12h)
Sources: Page: p.1863
unhealthy, 59.6
n = 273
Health Status: unhealthy
Condition: Community-acquired bacterial pneumonia
Age Group: 59.6
Sex: M+F
Population Size: 273
Sources: Page: p.1863
Disc. AE: Erythema, QT interval prolonged...
AEs leading to
discontinuation/dose reduction:
Erythema (0.37%)
QT interval prolonged (1%)
Angioedema (serious, 0.37%)
Sources: Page: p.1863
400 mg 1 times / day multiple, oral|intravenous
Recommended
Dose: 400 mg, 1 times / day
Route: oral|intravenous
Route: multiple
Dose: 400 mg, 1 times / day
Sources: Page: p.1
unhealthy
Health Status: unhealthy
Condition: Bacterial infections
Sources: Page: p.1
Disc. AE: Tendinitis, Tendon rupture...
AEs leading to
discontinuation/dose reduction:
Tendinitis
Tendon rupture
Peripheral neuropathy
Central nervous system disorder NOS
Myasthenia gravis
Sources: Page: p.1
AEs

AEs

AESignificanceDosePopulation
Rash Disc. AE
400 mg 1 times / day multiple, intravenous
Recommended
Dose: 400 mg, 1 times / day
Route: intravenous
Route: multiple
Dose: 400 mg, 1 times / day
Sources: Page: p.8.9
unhealthy, 50
Health Status: unhealthy
Condition: Bacterial infections
Age Group: 50
Sex: M+F
Sources: Page: p.8.9
Diarrhea >0.3
Disc. AE
400 mg 1 times / day multiple, oral
Recommended
Dose: 400 mg, 1 times / day
Route: oral
Route: multiple
Dose: 400 mg, 1 times / day
Sources: Page: p.8.9
unhealthy, 50
Health Status: unhealthy
Condition: Bacterial infections
Age Group: 50
Sex: M+F
Sources: Page: p.8.9
Dizziness >0.3
Disc. AE
400 mg 1 times / day multiple, oral
Recommended
Dose: 400 mg, 1 times / day
Route: oral
Route: multiple
Dose: 400 mg, 1 times / day
Sources: Page: p.8.9
unhealthy, 50
Health Status: unhealthy
Condition: Bacterial infections
Age Group: 50
Sex: M+F
Sources: Page: p.8.9
Nausea >0.3
Disc. AE
400 mg 1 times / day multiple, oral
Recommended
Dose: 400 mg, 1 times / day
Route: oral
Route: multiple
Dose: 400 mg, 1 times / day
Sources: Page: p.8.9
unhealthy, 50
Health Status: unhealthy
Condition: Bacterial infections
Age Group: 50
Sex: M+F
Sources: Page: p.8.9
Vomiting >0.3
Disc. AE
400 mg 1 times / day multiple, oral
Recommended
Dose: 400 mg, 1 times / day
Route: oral
Route: multiple
Dose: 400 mg, 1 times / day
Sources: Page: p.8.9
unhealthy, 50
Health Status: unhealthy
Condition: Bacterial infections
Age Group: 50
Sex: M+F
Sources: Page: p.8.9
Erythema 0.37%
Disc. AE
400 mg 1 times / day multiple, oral|intravenous
Recommended
Dose: 400 mg, 1 times / day
Route: oral|intravenous
Route: multiple
Dose: 400 mg, 1 times / day
Co-administed with::
Linezolid, IV(600 mg q12h)
Sources: Page: p.1863
unhealthy, 59.6
n = 273
Health Status: unhealthy
Condition: Community-acquired bacterial pneumonia
Age Group: 59.6
Sex: M+F
Population Size: 273
Sources: Page: p.1863
QT interval prolonged 1%
Disc. AE
400 mg 1 times / day multiple, oral|intravenous
Recommended
Dose: 400 mg, 1 times / day
Route: oral|intravenous
Route: multiple
Dose: 400 mg, 1 times / day
Co-administed with::
Linezolid, IV(600 mg q12h)
Sources: Page: p.1863
unhealthy, 59.6
n = 273
Health Status: unhealthy
Condition: Community-acquired bacterial pneumonia
Age Group: 59.6
Sex: M+F
Population Size: 273
Sources: Page: p.1863
Angioedema serious, 0.37%
Disc. AE
400 mg 1 times / day multiple, oral|intravenous
Recommended
Dose: 400 mg, 1 times / day
Route: oral|intravenous
Route: multiple
Dose: 400 mg, 1 times / day
Co-administed with::
Linezolid, IV(600 mg q12h)
Sources: Page: p.1863
unhealthy, 59.6
n = 273
Health Status: unhealthy
Condition: Community-acquired bacterial pneumonia
Age Group: 59.6
Sex: M+F
Population Size: 273
Sources: Page: p.1863
Central nervous system disorder NOS Disc. AE
400 mg 1 times / day multiple, oral|intravenous
Recommended
Dose: 400 mg, 1 times / day
Route: oral|intravenous
Route: multiple
Dose: 400 mg, 1 times / day
Sources: Page: p.1
unhealthy
Health Status: unhealthy
Condition: Bacterial infections
Sources: Page: p.1
Myasthenia gravis Disc. AE
400 mg 1 times / day multiple, oral|intravenous
Recommended
Dose: 400 mg, 1 times / day
Route: oral|intravenous
Route: multiple
Dose: 400 mg, 1 times / day
Sources: Page: p.1
unhealthy
Health Status: unhealthy
Condition: Bacterial infections
Sources: Page: p.1
Peripheral neuropathy Disc. AE
400 mg 1 times / day multiple, oral|intravenous
Recommended
Dose: 400 mg, 1 times / day
Route: oral|intravenous
Route: multiple
Dose: 400 mg, 1 times / day
Sources: Page: p.1
unhealthy
Health Status: unhealthy
Condition: Bacterial infections
Sources: Page: p.1
Tendinitis Disc. AE
400 mg 1 times / day multiple, oral|intravenous
Recommended
Dose: 400 mg, 1 times / day
Route: oral|intravenous
Route: multiple
Dose: 400 mg, 1 times / day
Sources: Page: p.1
unhealthy
Health Status: unhealthy
Condition: Bacterial infections
Sources: Page: p.1
Tendon rupture Disc. AE
400 mg 1 times / day multiple, oral|intravenous
Recommended
Dose: 400 mg, 1 times / day
Route: oral|intravenous
Route: multiple
Dose: 400 mg, 1 times / day
Sources: Page: p.1
unhealthy
Health Status: unhealthy
Condition: Bacterial infections
Sources: Page: p.1
PubMed

PubMed

TitleDatePubMed
In vitro activity of Bay 12-8039, a new 8-methoxyquinolone.
1997 Aug
Activity of moxifloxacin against mycobacteria.
1999 Sep
Antibacterial spectrum of a novel des-fluoro(6) quinolone, BMS-284756.
2000 Dec
In vitro susceptibility and eradication of Chlamydia pneumoniae cardiovascular strains from coronary artery endothelium and smooth muscle cells.
2001
Evidence of different profiles of side effects and drug-drug interactions among the quinolones--the pharmacokinetic standpoint.
2001
Comparison of side effects of levofloxacin versus other fluoroquinolones.
2001
Evaluation of the influence of antacids and H2 antagonists on the absorption of moxifloxacin after oral administration of a 400mg dose to healthy volunteers.
2001
Effects of dairy products on the oral bioavailability of moxifloxacin, a novel 8-methoxyfluoroquinolone, in healthy volunteers.
2001
Activity of moxifloxacin against clinical isolates of Streptococcus pneumoniae from England and Wales.
2001 Apr
Determination of moxifloxacin in growth media by high-performance liquid chromatography.
2001 Apr 15
A whole blood bactericidal assay for tuberculosis.
2001 Apr 15
Fluoroquinolone susceptibility, resistance, and pharmacodynamics versus clinical isolates of Streptococcus pneumoniae from Indiana.
2001 Aug
In vitro activity of fosfomycin in combination with various antistaphylococcal substances.
2001 Aug
Advances in DNA gyrase inhibitors.
2001 Feb
Efficacy of moxifloxacin, trovafloxacin, clinafloxacin and levofloxacin against intracellular Legionella pneumophila.
2001 Feb
Oral moxifloxacin vs high-dosage amoxicillin in the treatment of mild-to-moderate, community-acquired, suspected pneumococcal pneumonia in adults.
2001 Jan
Measurement of the bactericidal activity of fluoroquinolones against Streptococcus pneumoniae using the bactericidal index method.
2001 Jan
Drug Points: tachycardia associated with moxifloxacin.
2001 Jan 6
In vitro development of resistance to three quinolones in Streptococcus pneumoniae.
2001 Jan-Feb
Ciprofloxacin- and methicillin-resistant staphylococcus aureus susceptible to moxifloxacin, levofloxacin, teicoplanin, vancomycin and linezolid.
2001 Jul
Comparative in vitro bacteriostatic and bactericidal activity of trovafloxacin, levofloxacin and moxifloxacin against clinical and environmental isolates of Legionella spp.
2001 Jul
The use of fluoroquinolones as antiinfective transition-therapy agents in community-acquired pneumonia.
2001 Jul
[Hypertensive crisis and transitory left brunch block with QT interval prolongation associated to moxifloxacin].
2001 Jul 7
Microbial drug resistance and the roles of the new antibiotics.
2001 Jun
What do the new antimicrobials offer? Weighing the advantages and disadvantages compared with traditional agents.
2001 Mar
Adverse reactions to fluoroquinolones. an overview on mechanistic aspects.
2001 Mar
Pharmacodynamics of moxifloxacin and levofloxacin against Staphylococcus aureus and Staphylococcus epidermidis in an in vitro pharmacodynamic model.
2001 Mar 15
Comparative in vitro activity of moxifloxacin by E-test against Streptococcus pyogenes.
2001 Mar 15
Penicillin-resistant streptococcus pneumoniae: review of moxifloxacin activity.
2001 Mar 15
Moxifloxacin in acute exacerbations of chronic bronchitis: clinical evaluation and assessment by patients.
2001 Mar-Apr
Comparison of antimicrobial in vitro activities against Streptococcus pneumoniae independent of MIC susceptibility breakpoints using MIC frequency distribution curves, scattergrams and linear regression analyses.
2001 Nov
[Diagnosis and therapy of abscess forming pneumonia].
2001 Oct
Clinical isolates of Streptococcus pneumoniae resistant to levofloxacin contain mutations in both gyrA and parC genes.
2001 Oct
Pharmacokinetics and pharmacodynamics of fluoroquinolones.
2001 Oct
Fluoroquinolone susceptibilities of efflux-mediated multidrug-resistant Pseudomonas aeruginosa, Stenotrophomonas maltophilia and Burkholderia cepacia.
2001 Oct
In vitro activity of novel fluoroquinolones against Streptococcus pneumoniae isolated from children with acute otitis media.
2001 Sep-Oct
Patents

Sample Use Guides

The dose of AVELOX is 400 mg (orally or as an intravenous infusion) once every 24 hours. The duration of therapy depends on the type of infection (5--21 days).
Route of Administration: Oral
In Vitro Use Guide
Phagocytosed bacteria were divided into four aliquots with different concentrations of the drug (0, 0.1, 1 and 10 MIC). At baseline and after 1, 2 and 4 h incubation, the number of viable bacteria was determined by a subculture technique. Moxifloxacin was active against all tested staphylococci with MICs of 0.063–2 mg/L.
Substance Class Chemical
Created
by admin
on Sat Dec 16 16:55:37 UTC 2023
Edited
by admin
on Sat Dec 16 16:55:37 UTC 2023
Record UNII
U188XYD42P
Record Status Validated (UNII)
Record Version
  • Download
Name Type Language
MOXIFLOXACIN
INN   MI   VANDF   WHO-DD  
INN  
Official Name English
moxifloxacin [INN]
Common Name English
AVELOX IV
Brand Name English
1-CYCLOPROPYL-6-FLUORO-1,4-DIHYDRO-8-METHOXY-7-((4AS,7AS)-OCTAHYDRO-6H-PYRROLO(3,4-B)PYRIDIN-6-YL)-4-OXO-3-QUINOLINECARBOXYLIC ACID
Common Name English
Moxifloxacin [WHO-DD]
Common Name English
MOXIFLOXACIN [VANDF]
Common Name English
ZIMOXIN
Brand Name English
MOXIFLOXACIN [MI]
Common Name English
Classification Tree Code System Code
WHO-ATC S01AX22
Created by admin on Sat Dec 16 16:55:39 UTC 2023 , Edited by admin on Sat Dec 16 16:55:39 UTC 2023
WHO-ATC J01MA14
Created by admin on Sat Dec 16 16:55:39 UTC 2023 , Edited by admin on Sat Dec 16 16:55:39 UTC 2023
NCI_THESAURUS C795
Created by admin on Sat Dec 16 16:55:39 UTC 2023 , Edited by admin on Sat Dec 16 16:55:39 UTC 2023
NDF-RT N0000175937
Created by admin on Sat Dec 16 16:55:39 UTC 2023 , Edited by admin on Sat Dec 16 16:55:39 UTC 2023
WHO-VATC QS01AE07
Created by admin on Sat Dec 16 16:55:39 UTC 2023 , Edited by admin on Sat Dec 16 16:55:39 UTC 2023
WHO-VATC QJ01MA14
Created by admin on Sat Dec 16 16:55:39 UTC 2023 , Edited by admin on Sat Dec 16 16:55:39 UTC 2023
LIVERTOX NBK548166
Created by admin on Sat Dec 16 16:55:39 UTC 2023 , Edited by admin on Sat Dec 16 16:55:39 UTC 2023
WHO-ATC S01AE07
Created by admin on Sat Dec 16 16:55:39 UTC 2023 , Edited by admin on Sat Dec 16 16:55:39 UTC 2023
NDF-RT N0000007606
Created by admin on Sat Dec 16 16:55:39 UTC 2023 , Edited by admin on Sat Dec 16 16:55:39 UTC 2023
Code System Code Type Description
INN
7659
Created by admin on Sat Dec 16 16:55:39 UTC 2023 , Edited by admin on Sat Dec 16 16:55:39 UTC 2023
PRIMARY
HSDB
8026
Created by admin on Sat Dec 16 16:55:39 UTC 2023 , Edited by admin on Sat Dec 16 16:55:39 UTC 2023
PRIMARY
NCI_THESAURUS
C62052
Created by admin on Sat Dec 16 16:55:39 UTC 2023 , Edited by admin on Sat Dec 16 16:55:39 UTC 2023
PRIMARY
WIKIPEDIA
MOXIFLOXACIN
Created by admin on Sat Dec 16 16:55:39 UTC 2023 , Edited by admin on Sat Dec 16 16:55:39 UTC 2023
PRIMARY
CHEBI
63611
Created by admin on Sat Dec 16 16:55:39 UTC 2023 , Edited by admin on Sat Dec 16 16:55:39 UTC 2023
PRIMARY
DAILYMED
U188XYD42P
Created by admin on Sat Dec 16 16:55:39 UTC 2023 , Edited by admin on Sat Dec 16 16:55:39 UTC 2023
PRIMARY
LACTMED
Moxifloxacin
Created by admin on Sat Dec 16 16:55:39 UTC 2023 , Edited by admin on Sat Dec 16 16:55:39 UTC 2023
PRIMARY
PUBCHEM
152946
Created by admin on Sat Dec 16 16:55:39 UTC 2023 , Edited by admin on Sat Dec 16 16:55:39 UTC 2023
PRIMARY
CAS
151096-09-2
Created by admin on Sat Dec 16 16:55:39 UTC 2023 , Edited by admin on Sat Dec 16 16:55:39 UTC 2023
PRIMARY
EVMPD
SUB09086MIG
Created by admin on Sat Dec 16 16:55:39 UTC 2023 , Edited by admin on Sat Dec 16 16:55:39 UTC 2023
PRIMARY
ChEMBL
CHEMBL32
Created by admin on Sat Dec 16 16:55:39 UTC 2023 , Edited by admin on Sat Dec 16 16:55:39 UTC 2023
PRIMARY
MERCK INDEX
m7647
Created by admin on Sat Dec 16 16:55:39 UTC 2023 , Edited by admin on Sat Dec 16 16:55:39 UTC 2023
PRIMARY Merck Index
RXCUI
139462
Created by admin on Sat Dec 16 16:55:39 UTC 2023 , Edited by admin on Sat Dec 16 16:55:39 UTC 2023
PRIMARY RxNorm
FDA UNII
U188XYD42P
Created by admin on Sat Dec 16 16:55:39 UTC 2023 , Edited by admin on Sat Dec 16 16:55:39 UTC 2023
PRIMARY
SMS_ID
100000080618
Created by admin on Sat Dec 16 16:55:39 UTC 2023 , Edited by admin on Sat Dec 16 16:55:39 UTC 2023
PRIMARY
DRUG BANK
DB00218
Created by admin on Sat Dec 16 16:55:39 UTC 2023 , Edited by admin on Sat Dec 16 16:55:39 UTC 2023
PRIMARY
CAS
354812-41-2
Created by admin on Sat Dec 16 16:55:39 UTC 2023 , Edited by admin on Sat Dec 16 16:55:39 UTC 2023
NON-SPECIFIC STEREOCHEMISTRY
MESH
C104727
Created by admin on Sat Dec 16 16:55:39 UTC 2023 , Edited by admin on Sat Dec 16 16:55:39 UTC 2023
PRIMARY
DRUG CENTRAL
1854
Created by admin on Sat Dec 16 16:55:39 UTC 2023 , Edited by admin on Sat Dec 16 16:55:39 UTC 2023
PRIMARY
EPA CompTox
DTXSID3048491
Created by admin on Sat Dec 16 16:55:39 UTC 2023 , Edited by admin on Sat Dec 16 16:55:39 UTC 2023
PRIMARY
Related Record Type Details
TARGET ORGANISM->INHIBITOR
TARGET ORGANISM->INHIBITOR
TARGET ORGANISM->INHIBITOR
DEGRADENT -> PARENT
TARGET ORGANISM->INHIBITOR
BINDER->LIGAND
BINDING
TARGET ORGANISM->INHIBITOR
TARGET ORGANISM->INHIBITOR
SALT/SOLVATE -> PARENT
TARGET ORGANISM->INHIBITOR
TARGET ORGANISM->INHIBITOR
TARGET -> INHIBITOR
SALT/SOLVATE -> PARENT
Related Record Type Details
METABOLITE INACTIVE -> PARENT
MINOR
PLASMA; URINE
METABOLITE INACTIVE -> PARENT
MAJOR
FECAL; PLASMA
Related Record Type Details
IMPURITY -> PARENT
IMPURITY -> PARENT
Related Record Type Details
ACTIVE MOIETY
Name Property Type Amount Referenced Substance Defining Parameters References
MIC BIOLOGICAL SUSCEPTIBILITY: RESISTANT

PATHOGEN:l E. FAECALIS, S. PNEUMONIAE, STREPTOCOCCUS SPECIES

MIC BIOLOGICAL SUSCEPTIBILITY: SUSCEPTIBLE

PATHOGEN:l E. FAECALIS, H. INFLUENZAE, H. PARAINFLUENZAE, S. PNEUMONIAE, STREPTOCOCCUS SPECIES

Biological Half-life PHARMACOKINETIC DOSE FREQUENCY: SINGLE DOSE

ROUTE OF ADMINISTRATION: IV

MIC BIOLOGICAL SUSCEPTIBILITY: INTERMEDIATE

PATHOGEN: S. AUREUS

ORAL BIOAVAILABILITY PHARMACOKINETIC
MIC BIOLOGICAL SUSCEPTIBILITY: SUSCEPTIBLE

PATHOGEN: S. AUREUS

MIC BIOLOGICAL SUSCEPTIBILITY: RESISTANT

PATHOGEN: ENTEROBACTERIACAE, ANEROBIC BACTERIA

Volume of Distribution PHARMACOKINETIC
MIC BIOLOGICAL SUSCEPTIBILITY: SUSCEPTIBLE

PATHOGEN: ENTEROBACTERIACAE, ANAEROBIC BACTERIA

MIC BIOLOGICAL PATHOGEN: ENTEROBACTERIACAE, ANEROBIC BACTERIA

SUSCEPTIBILITY: INTERMEDIATE

MIC BIOLOGICAL SUSCEPTIBILITY: INTERMEDIATE

PATHOGEN:l E. FAECALIS, S. PNEUMONIAE, STREPTOCOCCUS SPECIES

Biological Half-life PHARMACOKINETIC DOSE FREQUENCY: SINGLE DOSE

ROUTE OF ADMINISTRATION: ORAL

MIC BIOLOGICAL PATHOGEN: Y. PESTIS

SUSCEPTIBILITY: SUSCEPTIBLE